Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation (TRANSFORM)

Correlative ctDNA analysis of TRANSFORM (liso-cel vs salvage chemo + ASCT in second-line LBCL) in 136 patients. ctDNA clearance (MRD-neg) predicted longer EFS at all time points in both arms, with significantly more liso-cel-treated patients achieving MRD-neg. MRD-neg remained associated with EFS after adjusting for PET. Level 2.

J Clin OncolPubMed 42044466